Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024

免疫腫瘍学におけるアッセイの世界市場予測(~2024年)

◆タイトル:Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024
◆商品コード:MD 6896
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年2月20日
◆ページ数:109
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

免疫腫瘍学におけるアッセイの世界市場は、2018年の29億米ドルから2024年には59億米ドルに達し、この期間中12.7%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、伝統的な治療法を超える標的治療法の採用の増加、mAbの需要の増加などが考えられます。一方で、免疫療法治療の高コストと製品開発サイクルにおける高い消耗率は、この市場の成長を抑制すると考えられる主な要因です。当調査レポートでは、免疫腫瘍学におけるアッセイの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品(消耗品、ソフトウェア)分析、技術(イムノアッセイ、フローサイトメトリー、PCR、次世代シーケンシング)分析、適応症(肺がん、大腸がん)分析、用途(研究、臨床診断)分析、免疫腫瘍学におけるアッセイの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The increasing adoption of targeted therapy over traditional therapy is expected to drive the overall growth of the immuno-oncology assays market.”The immuno-oncology assays market is expected to grow from USD 2.9 billion in 2018 to USD 5.9 billion by 2024, at a CAGR of 12.7% during the forecast period. The immuno-oncology assays market is driven primarily by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period.
“The lung cancer segment is expected to grow at the highest CAGR during the forecast period.”

Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer, and other cancers. The lung cancer segment is expected to be the fastest-growing segment during the forecast period, as major players are focusing on immuno-oncology research for lung cancer owing to its increasing incidence.
“Asia Pacific projected to grow at the highest CAGR during the forecast period.”
The Asia Pacific is projected to record the highest growth rate during the forecast period. Factors such as growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immuno-oncology assays market.
By Company Type: Tier 1: 18%, Tier 2: 39%, and Tier 3: 43%
By Designation: C-level Executives: 25%, Directors: 20%, and Others: 55%
By Region: North America: 40%, Europe: 27%, APAC: 20%, and RoW: 13%

The immuno-oncology assays market comprises major providers such as Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). The study includes an in-depth competitive analysis of these key players in the immuno-oncology assays market, along with their company profiles, recent developments, and key market strategies.
Research Coverage:
The market study covers the immuno-oncology assays market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, technology, application, indication, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 13
1.3.1 MARKETS COVERED 14
1.3.2 YEARS COVERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 PRIMARY DATA 17
2.1.1 KEY DATA FROM PRIMARY SOURCES 17
2.1.2 KEY INDUSTRY INSIGHTS 18
2.2 SECONDARY DATA 19
2.2.1 KEY DATA FROM SECONDARY SOURCES 19
2.3 MARKET SIZE ESTIMATION 19
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.4.1 ASSUMPTIONS FOR THE STUDY 22
3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 27
4.1 IMMUNO-ONCOLOGY ASSAYS: MARKET OVERVIEW 27
4.2 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET,
BY PRODUCT AND COUNTRY (2018) 28
4.3 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION (2018 VS. 2024) 28
4.4 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY (2018 VS. 2024) 29
4.5 GEOGRAPHICAL SNAPSHOT OF THE IMMUNO-ONCOLOGY ASSAYS MARKET 29
5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.2 MARKET DYNAMICS 30
5.2.1 DRIVERS 31
5.2.1.1 Rising incidence of cancer and increasing adoption of targeted therapy 31
5.2.2 RESTRAINTS 31
5.2.2.1 Unfavorable regulatory and reimbursement scenario 31
5.2.2.2 High amount of capital investments and low benefit-cost ratio 32
5.2.3 OPPORTUNITIES 32
5.2.3.1 Companion diagnostics 32
6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT 33
6.1 INTRODUCTION 34
6.2 CONSUMABLES 34
6.2.1 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD 34
6.3 SOFTWARE 35
6.3.1 THE NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS HAS RESULTED IN THE INCREASED ADOPTION OF SOFTWARE 35
7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY 37
7.1 INTRODUCTION 38
7.2 PCR 38
7.2.1 EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH 38
7.3 IMMUNOASSAY 39
7.3.1 IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER IN THE EARLY STAGE 39
7.4 NGS 41
7.4.1 NGS SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 41
7.5 FLOW CYTOMETRY 42
7.5.1 FLOW CYTOMETRY PLAYS A CRITICAL ROLE IN CLINICAL RESEARCH STUDIES 42
7.6 OTHER TECHNOLOGIES 43
8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION 45
8.1 INTRODUCTION 46
8.2 LUNG CANCER 46
8.2.1 INCREASING R&D ACTIVITIES ON LUNG IMMUNO-ONCOLOGY ASSAYS IS A KEY MARKET DRIVER 46
8.3 COLORECTAL CANCER 48
8.3.1 HIGH SUCCESS RATE OF IMMUNO-ONCOLOGY ASSAYS IN CRC TREATMENT DECISIONS TO DRIVE MARKET GROWTH 48
8.4 MELANOMA 49
8.4.1 GROWING CASES OF MELANOMA TO DRIVE MARKET GROWTH 49
8.5 BLADDER CANCER 50
8.5.1 BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS 50
8.6 OTHER CANCERS 51

9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION 52
9.1 INTRODUCTION 53
9.2 RESEARCH APPLICATIONS 53
9.2.1 RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT AND CLINICAL TRIALS TO DRIVE THE RESEARCH APPLICATIONS MARKET 53
9.3 CLINICAL DIAGNOSTICS 54
9.3.1 BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING ITS ADOPTION IN CLINICAL DIAGNOSTICS 54
10 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION 56
10.1 INTRODUCTION 57
10.2 NORTH AMERICA 58
10.2.1 US 61
10.2.1.1 Increasing demand for immunotherapy medicine forms a key driver of market growth in the US 61
10.2.2 CANADA 63
10.2.2.1 High burden of cancer to drive the demand for immuno-oncology assays 63
10.3 EUROPE 65
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN SEVERAL EU COUNTRIES TO SUPPORT MARKET GROWTH 65
10.4 ASIA PACIFIC 67
10.4.1 INCREASING DEMAND FOR BETTER HEALTHCARE SERVICES IN DEVELOPING ECONOMIES WILL CONTRIBUTE TO MARKET GROWTH 67
10.5 REST OF THE WORLD 70
11 COMPETITIVE LANDSCAPE 73
11.1 OVERVIEW 73
11.2 VENDOR BENCHMARKING 73
11.3 COMPETITIVE LEADERSHIP MAPPING 74
11.3.1 VISIONARY LEADERS 74
11.3.2 INNOVATORS 74
11.3.3 DYNAMIC DIFFERENTIATORS 74
11.3.4 EMERGING COMPANIES 74
11.4 MARKET RANKING ANALYSIS, 2017 76
11.5 COMPETITIVE SITUATION AND TRENDS 77
11.5.1 COLLABORATIONS 77
11.5.2 PRODUCT LAUNCHES 77
11.5.3 ACQUISITIONS 78
11.5.4 EXPANSIONS 78

12 COMPANY PROFILES 79
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 THERMO FISHER SCIENTIFIC, INC. 79
12.2 ROCHE DIAGNOSTICS 82
12.3 AGILENT TECHNOLOGIES, INC. 84
12.4 ILLUMINA, INC. 86
12.5 NANOSTRING TECHNOLOGIES, INC. 88
12.6 SARTORIUS AG 90
12.7 FOUNDATION MEDICINE 92
12.8 HTG MOLECULAR DIAGNOSTICS, INC. 93
12.9 QIAGEN 95
12.10 MERCK 97
12.11 PERKINELMER 99

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 101
13.1 INSIGHTS OF INDUSTRY EXPERTS 101
13.2 DISCUSSION GUIDE 102
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 105
13.4 AVAILABLE CUSTOMIZATIONS 107
13.5 RELATED REPORTS 107
13.6 AUTHOR DETAILS 108

LIST OF TABLES

TABLE 1 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016–2024 (USD MILLION) 34
TABLE 2 IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION,
2016–2024 (USD MILLION) 34
TABLE 3 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES,
BY COUNTRY, 2016–2024 (USD MILLION) 35
TABLE 4 IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE, BY REGION,
2016–2024 (USD MILLION) 36
TABLE 5 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE,
BY COUNTRY, 2016–2024 (USD MILLION) 36
TABLE 6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 38
TABLE 7 IMMUNO-ONCOLOGY ASSAYS MARKET FOR PCR, BY REGION,
2016–2024 (USD MILLION) 39
TABLE 8 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR PCR,
BY COUNTRY, 2016–2024 (USD MILLION) 39
TABLE 9 IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY,
BY REGION, 2016–2024 (USD MILLION) 40
TABLE 10 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY,
BY COUNTRY, 2016–2024 (USD MILLION) 40
TABLE 11 IMMUNO-ONCOLOGY ASSAYS MARKET FOR NGS, BY REGION,
2016–2024 (USD MILLION) 41
TABLE 12 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR NGS,
BY COUNTRY, 2016–2024 (USD MILLION) 42
TABLE 13 IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY,
BY REGION, 2016–2024 (USD MILLION) 42
TABLE 14 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2016–2024 (USD MILLION) 43
TABLE 15 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2016–2024 (USD MILLION) 43
TABLE 16 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016–2024 (USD MILLION) 44
TABLE 17 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 46
TABLE 18 IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION,
2016–2024 (USD MILLION) 47
TABLE 19 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER,
BY COUNTRY, 2016–2024 (USD MILLION) 47
TABLE 20 IMMUN0-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY REGION, 2016–2024 (USD MILLION) 48
TABLE 21 NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2016–2024 (USD MILLION) 48
TABLE 22 IMMUN0-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION,
2016–2024 (USD MILLION) 49
TABLE 23 NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR MELANOMA,
BY COUNTRY, 2016–2024 (USD MILLION) 49
TABLE 24 IMMUN0-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION,
2016–2024 (USD MILLION) 50
TABLE 25 NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY COUNTRY, 2016–2024 (USD MILLION) 50
TABLE 26 IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY REGION,
2016–2024 (USD MILLION) 51
TABLE 27 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS,
BY COUNTRY, 2016–2024 (USD MILLION) 51
TABLE 28 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 53
TABLE 29 IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2016–2024 (USD MILLION) 54
TABLE 30 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2016–2024 (USD MILLION) 54
TABLE 31 IMMUNO-ONCOLOGY ASSAYS MARKET FOR APPLICATIONS, BY CLINICAL DIAGNOSTICS, 2016–2024 (USD MILLION) 55
TABLE 32 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2016–2024 (USD MILLION) 55
TABLE 33 IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2016–2024 (USD MILLION) 57
TABLE 34 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY,
2016–2024 (USD MILLION) 59
TABLE 35 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 59
TABLE 36 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 59
TABLE 37 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 60
TABLE 38 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 60
TABLE 39 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 61
TABLE 40 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 61
TABLE 41 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 62
TABLE 42 US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 62
TABLE 43 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 63
TABLE 44 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 63
TABLE 45 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 64
TABLE 46 CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 64
TABLE 47 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 65
TABLE 48 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 66
TABLE 49 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 66
TABLE 50 EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 67
TABLE 51 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 68
TABLE 52 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 69
TABLE 53 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 69
TABLE 54 APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 70
TABLE 55 ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2016–2024 (USD MILLION) 70
TABLE 56 ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2016–2024 (USD MILLION) 71
TABLE 57 ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2016–2024 (USD MILLION) 71
TABLE 58 ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2016–2024 (USD MILLION) 72
TABLE 59 VENDOR BENCHMARKING BY GROWTH STRATEGY 73
TABLE 60 COLLABORATIONS, 2016–2018 77
TABLE 61 PRODUCT LAUNCHES, 2016–2018 77
TABLE 62 ACQUISITIONS, 2016-2018 78
TABLE 63 EXPANSIONS, 2015 TO 2018 78


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 16
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 18
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20
FIGURE 5 DATA TRIANGULATION 21
FIGURE 6 IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION,
2018 VS. 2024 (USD MILLION) 23
FIGURE 7 IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT,
2018 VS. 2024 (USD MILLION) 24
FIGURE 8 IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION,
2018 VS. 2024 (USD MILLION) 24
FIGURE 9 IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY,
2018 VS. 2024 (USD MILLION) 25
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IMMUNO-ONCOLOGY ASSAYS MARKET 25
FIGURE 11 INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL
THERAPY IS A KEY DRIVER FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET 27
FIGURE 12 CONSUMABLES SEGMENT TO ACCOUNT FOR LARGEST SHARE IN NORTH AMERICAN IMMUNO-ONCOLOGY ASSAYS MARKET 28
FIGURE 13 RESEARCH APPLICATIONS TO CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET IN 2024 28
FIGURE 14 PCR SEGMENT WILL CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET IN 2024 29
FIGURE 15 APAC WILL BE THE FASTEST-GROWING MARKET FROM 2018 TO 2024 29
FIGURE 16 IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 30
FIGURE 17 NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT 58
FIGURE 18 ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT 68
FIGURE 19 IMMUNO-ONCOLOGY ASSAYS MARKET (GLOBAL), COMPETITIVE LEADERSHIP MAPPING, 2017 75
FIGURE 20 RANK OF COMPANIES IN THE GLOBAL IMMUNO-ONCOLOGY
ASSAYS MARKET, 2017 76
FIGURE 21 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017) 79
FIGURE 22 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017) 82
FIGURE 23 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2017) 84
FIGURE 24 ILLUMINA: COMPANY SNAPSHOT (2017) 86
FIGURE 25 NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT (2017) 88
FIGURE 26 SARTORIUS AG: COMPANY SNAPSHOT (2017) 90
FIGURE 27 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2017) 93
FIGURE 28 QIAGEN: COMPANY SNAPSHOT (2017) 95
FIGURE 29 MERCK: COMPANY SNAPSHOT (2017) 97
FIGURE 30 PERKINELMER: COMPANY SNAPSHOT (2017) 99


★調査レポート[免疫腫瘍学におけるアッセイの世界市場予測(~2024年)] ( Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024 / MD 6896) 販売に関する免責事項
[免疫腫瘍学におけるアッセイの世界市場予測(~2024年)] ( Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024 / MD 6896) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆